| Parasitic Diseases Research and Treatment | Lifetime | 14 | BE 1 | 99.23 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 82 | BE 3 | 99.37 |
| Infectious Diseases and Tuberculosis | Lifetime | 71 | BE 2 | 99.20 |
| HIV/AIDS Research and Interventions | Lifetime | 161 | BE 2 | 99.47 |
| Parasite Biology and Host Interactions | Lifetime | 83 | BE 1 | 99.01 |
| Tuberculosis Research and Epidemiology | Lifetime | 398 | BE 7 | 98.55 |
| Viral Infections and Outbreaks Research | Lifetime | 158 | BE 2 | 98.33 |
| HIV Research and Treatment | Lifetime | 521 | BE 10 | 98.67 |
| Parasites and Host Interactions | Lifetime | 262 | BE 8 | 98.06 |
| COVID-19 and Mental Health | Lifetime | 433 | BE 4 | 96.82 |
| Viral Infections and Vectors | Lifetime | 607 | BE 9 | 98.20 |
| Syphilis Diagnosis and Treatment | Lifetime | 127 | BE 2 | 97.32 |
| HIV/AIDS Impact and Responses | Lifetime | 118 | BE 5 | 97.06 |
| HIV/AIDS drug development and treatment | Lifetime | 657 | BE 17 | 97.93 |
| HIV-related health complications and treatments | Lifetime | 295 | BE 1 | 97.54 |
| Insects and Parasite Interactions | Lifetime | 93 | BE 1 | 96.53 |
| Diagnosis and treatment of tuberculosis | Lifetime | 307 | BE 6 | 96.08 |
| Adolescent Sexual and Reproductive Health | Lifetime | 645 | BE 5 | 97.12 |
| Disaster Response and Management | Lifetime | 415 | BE 6 | 95.74 |
| HIV, Drug Use, Sexual Risk | Lifetime | 640 | BE 2 | 96.86 |
| Travel-related health issues | Lifetime | 236 | BE 5 | 92.51 |
| COVID-19 Pandemic Impacts | Lifetime | 692 | BE 2 | 89.04 |
| Infectious Encephalopathies and Encephalitis | Lifetime | 934 | BE 7 | 81.31 |
| Parasite Biology and Host Interactions | 2021-2025 | 2 | BE 1 | 99.62 |
| Parasitic Diseases Research and Treatment | 2021-2025 | 2 | BE 1 | 99.47 |
| Insects and Parasite Interactions | 2021-2025 | 2 | BE 1 | 98.33 |
| Parasites and Host Interactions | 2021-2025 | 51 | BE 2 | 97.20 |
| COVID-19 and Mental Health | 2021-2025 | 625 | BE 10 | 94.99 |
| Epilepsy research and treatment | 2021-2025 | 422 | BE 6 | 93.16 |
| COVID-19 epidemiological studies | 2021-2025 | 967 | BE 14 | 90.40 |
| COVID-19 Pandemic Impacts | 2021-2025 | 515 | BE 1 | 87.40 |